Fig. 3

Antithrombotic treatment use by stroke risk in eligible patients from China at Phase II and Phase III.

Stroke risk stratification by CHA₂DS₂-VASc score: low (score = 1 for females); moderate (score = 1 for males or 2 for females); high (score ≥ 2 for males or ≥ 3 for females). AP, antiplatelet therapy; NOAC, non-VKA oral anticoagulant; VKA, vitamin K antagonist. None indicates no antithrombotic treatment